Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1986 Jan 1;163(1):18–40. doi: 10.1084/jem.163.1.18

A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells

PMCID: PMC2188018  PMID: 2416868

Abstract

Human T leukemia cell lines spontaneously release into their medium a suppressor lymphokine, T leukemia-derived suppressor lymphokine (TLSL), able to inhibit proliferation, DNA synthesis, and colony formation in a variety of malignant hemopoietic cell lines, as well as in normal myelomonocytic progenitor cells from bone marrow and peripheral blood. Titration curves indicated that the inhibitory activity in the crude supernatant preparations ranged from 10(-3)-10(-9): the supernatants from CCRF/CEM, HUT-78, and MOLT-4 cell lines were the most active, those from HPB-ALL, JM, and CCRF/HSB2 displayed an intermediate activity, and the Jurkat supernatant was the least active. Target cell lines of B cell origin (Burkitt lymphomas) were more sensitive than granulocytic, monocytic, erythroid, and T cell lines. Partial purification by ammonium sulfate precipitation and column chromatography demonstrated that TLSL is a protein with an Mr of 88,000, as determined by gel filtration. A high Mr form (greater than 300,000) was produced in serum-free medium by one of the most active producer cell lines (CCRF/CEM), and appeared to be an aggregate of the 88,000 Mr form. Neither the partially purified fractions obtained nor the crude supernatant preparations displayed antiviral activity or contained interleukin 2. Unlike lymphotoxin and tumor necrosis factor, TLSL is cytostatic: maximal inhibition of proliferation was observed 4- 5 d after addition of crude supernatant to the target cells, and was not accompanied by a significant loss in cell viability. The antiproliferative capacity of TLSL was manifested both in suspension and methylcellulose cultures. Treated target cells accumulated either in the G1 or in the S phase of the cell cycle. The effect of TLSL on the target cells is irreversible: even brief (1 h) incubation of sensitive cells with TLSL resulted in inhibition of proliferation measured 5 d later. Although TLSL is produced by leukemic T cell lines, this lymphokine inhibits proliferation of normal peripheral blood T cells in response to mitogens or alloantigens: T lymphocyte activation was inhibited by all of the T cell supernatants tested. In contrast, when T cell lines were used as targets, no inhibition of proliferation was detected with two exceptions: the low producer Jurkat cell line was sensitive to all the T cell-derived supernatants, and the intermediate producer CCRF/HSB2 cell line was sensitive only to the three most active supernatants, CCRF/CEM, MOLT-4, and HUT-78. The possible significance of TLSL and its relationship with other suppressor lymphokines previously described in other systems is discussed.

Full Text

The Full Text of this article is available as a PDF (1.4 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams R. A., Flowers A., Davis B. J. Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2. Cancer Res. 1968 Jun;28(6):1121–1125. [PubMed] [Google Scholar]
  2. Aune T. M., Webb D. R., Pierce C. W. Purification and initial characterization of the lymphokine soluble immune response suppressor. J Immunol. 1983 Dec;131(6):2848–2852. [PubMed] [Google Scholar]
  3. Baserga R. The cell cycle. N Engl J Med. 1981 Feb 19;304(8):453–459. doi: 10.1056/NEJM198102193040803. [DOI] [PubMed] [Google Scholar]
  4. Basham T. Y., Merigan T. C. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol. 1983 Apr;130(4):1492–1494. [PubMed] [Google Scholar]
  5. Chiba K., Nishimura T., Hashimoto Y. Stimulated rat T cell-derived inhibitory factor for cellular DNA synthesis (STIF). I. Isolation and characterization. J Immunol. 1985 Feb;134(2):1019–1025. [PubMed] [Google Scholar]
  6. Devlin J. J., Klostergaard J., Granger G. A. Isolation and identification of an alpha 2 subclass lymphotoxin (LT) subunit from the high-molecular-weight (complex) human LT class. Cell Immunol. 1984 Oct 15;88(2):297–308. doi: 10.1016/0008-8749(84)90163-1. [DOI] [PubMed] [Google Scholar]
  7. FOLEY G. E., LAZARUS H., FARBER S., UZMAN B. G., BOONE B. A., MCCARTHY R. E. CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer. 1965 Apr;18:522–529. doi: 10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  8. Ferrero D., Rovera G. Human leukaemic cell lines. Clin Haematol. 1984 Jun;13(2):461–487. [PubMed] [Google Scholar]
  9. Fleisher T. A., Greene W. C., Blaese R. M., Waldmann T. A. Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. II. Characterization of a soluble suppressor of B cell immunoglobulin production. J Immunol. 1981 Mar;126(3):1192–1197. [PubMed] [Google Scholar]
  10. Gazdar A. F., Carney D. N., Bunn P. A., Russell E. K., Jaffe E. S., Schechter G. P., Guccion J. G. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood. 1980 Mar;55(3):409–417. [PubMed] [Google Scholar]
  11. Granger G. A., Moore G. E., White J. G., Matzinger P., Sundsmo J. S., Shupe S., Kolb W. P., Kramer J., Glade P. R. Production of lymphotoxin and migration inhibitory factor by established human lymphocytic cell lines. J Immunol. 1970 Jun;104(6):1476–1485. [PubMed] [Google Scholar]
  12. Gray P. W., Leung D. W., Pennica D., Yelverton E., Najarian R., Simonsen C. C., Derynck R., Sherwood P. J., Wallace D. M., Berger S. L. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 1982 Feb 11;295(5849):503–508. doi: 10.1038/295503a0. [DOI] [PubMed] [Google Scholar]
  13. Irons R. D., Pfeifer R. W., Aune T. M., Pierce C. W. Soluble immune response suppressor (SIRS) inhibits microtubule function in vivo and microtubule assembly in vitro. J Immunol. 1984 Oct;133(4):2032–2036. [PubMed] [Google Scholar]
  14. Jeffes E. W., Granger G. A. Relationship of cloning inhibition factor, "lymphotoxin" factor, and proliferation inhibition factor release in vitro by mitogen-activated human lymphoctes. J Immunol. 1975 Jan;114(1 Pt 1):64–69. [PubMed] [Google Scholar]
  15. Jegasothy B. V., Battles D. R. Immuno-suppressive lymphocyte factors-III. Complete purification and partial characterization of human inhibitor of DNA synthesis. Mol Immunol. 1981 May;18(5):395–401. doi: 10.1016/0161-5890(81)90101-2. [DOI] [PubMed] [Google Scholar]
  16. Kasakura S., Taguchi M., Murachi T., Uchino H., Hanaoka M. A new mediator (suppressor cell induction factor) activating T cell-mediated suppression: characterization of suppressor cells, kinetics of their generation, and mechanism of their action. J Immunol. 1983 Nov;131(5):2307–2315. [PubMed] [Google Scholar]
  17. Kasakura S., Taguchi M., Watanabe Y., Okubo T., Murachi T., Uchino H., Hanaoka M. Suppressor cell induction factor: a new mediator released by stimulated human lymphocytes and distinct from previously described lymphokines. J Immunol. 1983 Jun;130(6):2720–2726. [PubMed] [Google Scholar]
  18. Kawano M., Iwato K., Kuramoto A. Identification and characterization of a B cell growth inhibitory factor (BIF) on BCGF-dependent B cell proliferation. J Immunol. 1985 Jan;134(1):375–381. [PubMed] [Google Scholar]
  19. King D. P., Jones P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol. 1983 Jul;131(1):315–318. [PubMed] [Google Scholar]
  20. Lau C. Y., Budz-Tymkewycz S., Wang E. Y., Ishaque A. A mutant human T-cell line producing immunosuppressive factor(s). Cell Immunol. 1984 Aug;87(1):35–52. doi: 10.1016/0008-8749(84)90128-x. [DOI] [PubMed] [Google Scholar]
  21. Lau C. Y., Wang E. Y., Li D., Budz-Tymkewycz S., Visconti V., Ishaque A. Mechanism of action of a suppressor-activating factor (SAF) produced by a human T cell line. J Immunol. 1985 May;134(5):3155–3162. [PubMed] [Google Scholar]
  22. Lee S. C., Lucas Z. J. Regulatory factors produced by lymphocytes. II. Inhibition of cellular DNA synthesis associated with a factor inhibiting DNA polymerase alpha activity. J Immunol. 1977 Jan;118(1):88–97. [PubMed] [Google Scholar]
  23. Lee S. H., Aggarwal B. B., Rinderknecht E., Assisi F., Chiu H. The synergistic anti-proliferative effect of gamma-interferon and human lymphotoxin. J Immunol. 1984 Sep;133(3):1083–1086. [PubMed] [Google Scholar]
  24. Minowada J., Onuma T., Moore G. E. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst. 1972 Sep;49(3):891–895. [PubMed] [Google Scholar]
  25. Morikawa S., Tatsumi E., Baba M., Harada T., Yasuhira K. Two E-rosette-forming lymphoid cell lines. Int J Cancer. 1978 Feb 15;21(2):166–170. doi: 10.1002/ijc.2910210207. [DOI] [PubMed] [Google Scholar]
  26. Namba Y., Jegasothy B. V., Waksman B. H. Regulatory substances produced by lymphocytes. V. Production of inhibitor of DNA synthesis (IDS) by proliferating T lymphocytes. J Immunol. 1977 Apr;118(4):1379–1384. [PubMed] [Google Scholar]
  27. Papageorgiou P. S., Sorokin C. F., Glade P. R. Similarity of migration inhibitory factor(s) produced by human lymphoid cell line and phytohemagglutinin and tuberculin-stimulated human peripheral lymphocytes. J Immunol. 1974 Feb;112(2):675–682. [PubMed] [Google Scholar]
  28. Pennica D., Nedwin G. E., Hayflick J. S., Seeburg P. H., Derynck R., Palladino M. A., Kohr W. J., Aggarwal B. B., Goeddel D. V. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984 Dec 20;312(5996):724–729. doi: 10.1038/312724a0. [DOI] [PubMed] [Google Scholar]
  29. Pessano S., McNab A., Rovera G. Growth and differentiation of human and murine erythroleukemia cell lines in serum-free synthetic medium. Cancer Res. 1981 Sep;41(9 Pt 1):3592–3596. [PubMed] [Google Scholar]
  30. Rich R. R., Pierce C. W. Biological expressions of lymphocyte activation. 3. Suppression of plaque-forming cell responses in vitro by supernatant fluids from concanavalin A-activated spleen cell cultures. J Immunol. 1974 Apr;112(4):1360–1368. [PubMed] [Google Scholar]
  31. Santoli D., Defreitas E. C., Sandberg-Wollheim M., Francis M. K., Koprowski H. Phenotypic and functional characterization of T cell clones derived from the cerebrospinal fluid of multiple sclerosis patients. J Immunol. 1984 May;132(5):2386–2392. [PubMed] [Google Scholar]
  32. Santoli D., Francis M. K., Matera L., Ferrero D. Induction of proliferation and NK activity in human lymphocytes by mature myelomonocytic cells: evidence for an HLA-DR-independent MLR stimulatory ability of terminally differentiated nonlymphoid leukemic cell lines and of normal peripheral blood granulocytes. J Immunol. 1983 Aug;131(2):736–742. [PubMed] [Google Scholar]
  33. Santoli D., Trinchieri G., Koprowski H. Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol. 1978 Aug;121(2):532–538. [PubMed] [Google Scholar]
  34. Santoli D., Trinchieri G., Moretta L., Zmijewski C. M., Koprowski H. Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol. 1978 Aug;33(2):309–318. [PMC free article] [PubMed] [Google Scholar]
  35. Schnaper H. W., Pierce C. W., Aune T. M. Identification and initial characterization of concanavalin A- and interferon-induced human suppressor factors: evidence for a human equivalent of murine soluble immune response suppressor (SIRS). J Immunol. 1984 May;132(5):2429–2435. [PubMed] [Google Scholar]
  36. Shirai T., Yamaguchi H., Ito H., Todd C. W., Wallace R. B. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. 1985 Feb 28-Mar 6Nature. 313(6005):803–806. doi: 10.1038/313803a0. [DOI] [PubMed] [Google Scholar]
  37. Spofford B. T., Daynes R. A., Granger G. A. Cell-mediated immunity in vitro: a highly sensitive assay for human lymphotoxin. J Immunol. 1974 Jun;112(6):2111–2116. [PubMed] [Google Scholar]
  38. Trucco M., Rovera G., Ferrero D. A novel human lymphokine that inhibits haematopoietic progenitor cell proliferation. Nature. 1984 May 10;309(5964):166–168. doi: 10.1038/309166a0. [DOI] [PubMed] [Google Scholar]
  39. Wilkins J. A., Sigurdson S. L., Rutherford W. J., Jordan Y., Warrington R. J. The production of immunoregulatory factors by a human macrophage-like cell line. I. Characterization of an inhibitor of lymphocyte DNA synthesis. Cell Immunol. 1983 Feb 1;75(2):328–336. doi: 10.1016/0008-8749(83)90330-1. [DOI] [PubMed] [Google Scholar]
  40. Yip Y. K., Barrowclough B. S., Urban C., Vilcek J. Molecular weight of human gamma interferon is similar to that of other human interferons. Science. 1982 Jan 22;215(4531):411–413. doi: 10.1126/science.6173921. [DOI] [PubMed] [Google Scholar]
  41. Yip Y. K., Pang R. H., Urban C., Vilcek J. Partial purification and characterization of human gamma (immune) interferon. Proc Natl Acad Sci U S A. 1981 Mar;78(3):1601–1605. doi: 10.1073/pnas.78.3.1601. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES